Wall Street brokerages forecast that Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) will post $410,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Infinity Pharmaceuticals’ earnings, with estimates ranging from $200,000.00 to $550,000.00. Infinity Pharmaceuticals reported sales of $440,000.00 during the same quarter last year, which indicates a negative year-over-year growth rate of 6.8%. The company is expected to issue its next earnings report on Tuesday, March 15th.
On average, analysts expect that Infinity Pharmaceuticals will report full-year sales of $1.68 million for the current financial year, with estimates ranging from $1.00 million to $1.96 million. For the next year, analysts expect that the firm will report sales of $1.65 million, with estimates ranging from $800,000.00 to $2.25 million. Zacks’ sales averages are an average based on a survey of research firms that follow Infinity Pharmaceuticals.
Infinity Pharmaceuticals (NASDAQ:INFI) last released its quarterly earnings results on Tuesday, November 2nd. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.02. Infinity Pharmaceuticals had a negative return on equity of 172.12% and a negative net margin of 2,398.81%. The business had revenue of $0.43 million during the quarter, compared to analysts’ expectations of $0.45 million. During the same period in the previous year, the business posted ($0.16) earnings per share.
Several institutional investors and hedge funds have recently modified their holdings of INFI. Legal & General Group Plc acquired a new position in shares of Infinity Pharmaceuticals in the 2nd quarter valued at approximately $27,000. IFP Advisors Inc acquired a new position in shares of Infinity Pharmaceuticals in the 3rd quarter valued at approximately $27,000. Barclays PLC acquired a new position in shares of Infinity Pharmaceuticals in the 1st quarter valued at approximately $30,000. Parametric Portfolio Associates LLC acquired a new position in Infinity Pharmaceuticals during the 2nd quarter worth approximately $31,000. Finally, Tradewinds Capital Management LLC acquired a new position in Infinity Pharmaceuticals during the 3rd quarter worth approximately $34,000. Institutional investors and hedge funds own 55.14% of the company’s stock.
NASDAQ:INFI traded up $0.05 on Thursday, hitting $2.27. 511,957 shares of the stock were exchanged, compared to its average volume of 3,849,047. The stock has a market capitalization of $202.06 million, a price-to-earnings ratio of -3.98 and a beta of 1.91. Infinity Pharmaceuticals has a 52 week low of $1.48 and a 52 week high of $5.98. The company’s 50-day moving average price is $2.80 and its 200 day moving average price is $2.98.
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. It focuses on drug development. The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.
Recommended Story: volatile stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.